

Financial Tear Sheet

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$10.93
Change (%)	▼ 0.3 (2.67%)
Volume	954,858
52 Week Low	\$11.05
Market Cap	\$343,516,403
Rolling EPS	-3.32
PE Ratio	N/A
Shares Outstanding	31,443,149

Data as of 04/20/18 1:02 p.m. ET



Recent Paratek Pharmaceuticals News & Events

04/19/18 - 8:45 a.m.

Paratek Pharmaceuticals, Inc. Prices \$140 Million of Convertible Senior Subordinated Notes due 2024

04/18/18 - 4:01 p.m.

Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of \$125 Million of Convertible Senior Subordinated Notes due 2024

04/13/18 - 4:40 p.m.

Paratek Appoints Rolf K. Hoffmann to Company’s Board of Directors

There are currently no events scheduled.

SEC Filings

Filing Date	Form
-------------	------

04/18/18	8-K
----------	-----

04/13/18	8-K
----------	-----

04/10/18	4
----------	---

04/10/18	4
----------	---

Management

Randy Brenner	Senior Vice President - Regulatory, Quality and Technical Operations
---------------	--

Jason Burdette	Vice President - Technical Operations
----------------	--

Jeanne Jew	Senior Vice President - Business Development
------------	---

Raj Padmanabhan	Vice President - Information Technology
-----------------	--

Regina Paglia	Senior Vice President - Human Resources
---------------	--

Susan Perkins, J.D.	Vice President - Intellectual Property
------------------------	---

Evan Tzanis	Senior Vice President - Clinical Development & Clinical Operations
-------------	--

Michael F. Bigham	Chief Executive Officer and Chairman of the Board
-------------------	---

Evan Loh, M.D. President, Chief
Operating Officer and
Chief Medical Officer

William Haskel General Counsel and
Corporate Secretary

Douglas W. Pagán Chief Financial Officer

Adam Woodrow Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.